UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2 G2019S carriers and in vivo

Neurology

Volumn 85, Issue 10, 2015, Pages 846-852

  Mortiboys, Heather ^a   Furmston, Rebecca ^b   Bronstad, Gunnar ^c   Aasly, Jan ^d   Elliott, Chris ^b   Bandmann, Oliver ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c Neurozym Biotech AS   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; LEUCINE RICH REPEAT KINASE 2; SMALL INTERFERING RNA; URSODEOXYCHOLIC ACID; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADULT; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; EVOKED VISUAL RESPONSE; FLOW CYTOMETRY; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MITOCHONDRION; NONHUMAN; OXYGEN CONSUMPTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY CHAIN; SKIN BIOPSY; TRANSGENIC DROSOPHILA; VISUAL IMPAIRMENT; AGED; ANIMAL; DROSOPHILA; DRUG EFFECTS; FEMALE; GENETICS; HETEROZYGOTE; MALE; MIDDLE AGED; TRANSGENIC ANIMAL; TREATMENT OUTCOME;

ADULT; AGED; ANIMALS; ANIMALS, GENETICALLY MODIFIED; DROSOPHILA; FEMALE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIA; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84948127199     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001905     Document Type: Article

References (26)

1. Lesage S, Durr A, Tazir M, et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 2006;354:422-423.
2. Greggio E, Jain S, Kingsbury A, et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 2006;23:329-341.
3. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. Kinase activity of mutant LRRK2 mediates neu-ronal toxicity. Nat Neurosci 2006;9:1231-1233.
4. Tsika E, Moore DJ. Mechanisms of LRRK2-mediated neurodegeneration. Curr Neurol Neurosci Rep 2012;12: 251-260.
5. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7:583-590.
6. Mortiboys H, Johansen KK, Aasly JO, Bandmann O. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 2010;75:2017-2020.
7. Papkovskaia TD, Chau KY, Inesta-Vaquera F, et al. G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization. Hum Mol Genet 2012;21:4201-4213.
8. Mortiboys H, Aasly J, Bandmann O. Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease. Brain 2013;136:3038-3050.
9. Hoepken HH, Gispert S, Morales B, et al. Mitochondrial dysfunction, peroxidation damage and changes in glutathi-one metabolism in PARK6. Neurobiol Dis 2007;25: 401-411.
10. Mortiboys H, Thomas KJ, Koopman WJ, et al. Mitochon-drial function and morphology are impaired in parkin-mutant fibroblasts. Ann Neurol 2008;64:555-565.
11. Afsari F, Christensen KV, Smith GP, et al. Abnormal visual gain control in a Parkinson's disease model. Hum Mol Genet 2014;23:4465-4478.
12. Hindle S, Afsari F, Stark M, et al. Dopaminergic expression of the Parkinsonian gene LRRK2-G2019S leads to non-autonomous visual neurodegeneration, accelerated by increased neural demands for energy. Hum Mol Genet 2013;22:2129-2140.
13. Grunewald AK, Arns B, Meier B, Brockmann K, Tadic V, Klein C. Does uncoupling protein 2 expression qualify as marker of disease status in LRRK2-associated PD? Anti-oxid Redox Signal 2014;20:1955-1960.
14. Cooper O, Seo H, Andrabi S, et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med 2012;4:141ra90.
15. Wang X, Yan MH, Fujioka H, et al. LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet 2012;21:1931-1944.
16. Orenstein SJ, Kuo SH, Tasset I, et al. Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci 2013; 16:394-406.
17. Vives-Bauza C, Przedborski S. Mitophagy: the latest prob lem for Parkinson's disease. Trends Mol Med 2011;17: 158-165.
18. Ng CH, Mok SZ, Koh C, et al. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurode-generation in Drosophila. J Neurosci 2009;29: 11257-11262.
19. Smith WW, Pei Z, Jiang H, et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci USA 2005;102:18676-18681.
20. Vincow ES, Merrihew G, Thomas RE, et al. The PINK1-Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo. Proc Natl Acad Sci USA 2013;110:6400-6405.
21. Johansen KK, Wang L, Aasly JO, et al. Metabolomic profiling in LRRK2-related Parkinson's disease. PLoS One 2009;4:e7551.
22. Sierra M, Sanchez-Juan P, Martinez-Rodriguez MI, et al. Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease. Neurology 2013; 80:621-626.
23. Lee BD, Shin JH, VanKampen J, et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 2010;9:998-1000.
24. Hohenester S, Oude-Elferink RP, Beuers U. Primary biliary cirrhosis. Semin Immunopathol 2009;31:283-307.
25. Parry GJ, Rodrigues CM, Aranha MM, et al. Safety, tol-erability, and cerebrospinal fluid penetration of ursodeox-ycholic acid in patients with amyotrophic lateral sclerosis. Clin Neuropharmacol 2010;33:17-21.
26. Castro-Caldas M, Carvalho AN, Rodrigues E, et al. Taur-oursodeoxycholic acid prevents MPTP-induced dopamin-ergic cell death in a mouse model of Parkinson's disease. Mol Neurobiol 2012;46:475-486.